BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/17/2020 9:42:32 AM | Browse: 497 | Download: 948
 |
Received |
|
2020-06-18 08:46 |
|
Peer-Review Started |
|
2020-06-18 08:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-18 16:58 |
|
Revised |
|
2020-10-15 06:42 |
|
Second Decision |
|
2020-11-05 10:06 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-05 19:25 |
|
Articles in Press |
|
2020-11-05 19:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-11-27 08:38 |
|
Typeset the Manuscript |
|
2020-12-14 09:54 |
|
Publish the Manuscript Online |
|
2020-12-17 09:42 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rahul Trimukhe, Preeti Vani, Arvind Patel and Vikas Salgotra |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Vikas Salgotra, MPhil, Senior Researcher, SLTL Medical Division, SLTL (Sahajanand Laser Technology Ltd.), E30, Electronics Estate, GIDC, Sector 26, Gandhinagar 382016, Gujarat, India. clinical@sltl.com |
| Key Words |
Coronary artery disease; Everolimus; Major adverse cardiac event; Retrospective; EverProTM; Myocardial infarction |
| Core Tip |
New-generation drug-eluting stents (DES) reduce risk of stent thrombosisbut everolimus-eluting coronary stent system (EES) exerts higher interaction with rapamycin complex 2, higher bioavailability, shorter half-life than sirolimus, decreases vascular inflammation and promotes rapid endothelialization; therefore, outperformed paclitaxel DES in safety and efficacy. EverProTM, a second-generation EES with biodegradable polymer and a 60 μm cobalt-chromium platform design, facilitates reduction of intra-arterial injury. This observational study enrolled 77 patients with coronary artery disease (CAD), implanted with EverProTM stent having completed 1-years’ follow-up from index procedure. Our findings suggested that EverProTM EES is safe and effective with no major adverse cardiac events/stent thrombosis up to 1 year in patients with CAD. |
| Publish Date |
2020-12-17 09:42 |
| Citation |
Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020; 12(12): 615-625 |
| URL |
https://www.wjgnet.com/1949-8462/full/v12/i12/615.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v12.i12.615 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
